PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
BackgroundLenvatinib, regorafenib and anti-programmed cell death protein-1 (PD-1) immunotherapy have shown promising clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure, respectively. However, the combination of the two treatments has not been reported....
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.958869/full |
| _version_ | 1811209654529687552 |
|---|---|
| author | Yongkang Xu Shumin Fu Kai Shang Jiayu Zeng Ye Mao |
| author_facet | Yongkang Xu Shumin Fu Kai Shang Jiayu Zeng Ye Mao |
| author_sort | Yongkang Xu |
| collection | DOAJ |
| description | BackgroundLenvatinib, regorafenib and anti-programmed cell death protein-1 (PD-1) immunotherapy have shown promising clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure, respectively. However, the combination of the two treatments has not been reported. We compared the efficacy of PD-1 inhibitors with lenvatinib (PL) and PD-1 inhibitors plus regorafenib (PR) in patients with advanced HCC in this study.MethodsWe conducted a retrospective study of advanced HCC patients who undergone PD-1 inhibitors combined with lenvatinib or regorafenib after failure of sorafenib at Second Affiliated Hospital of Nanchang University from July 2018 and December 2020. The overall survival (OS), progression-free survival (PFS), effective rates and treatment-related adverse events (TRAEs) were investigated.ResultsIn total, 61 patients met the criteria and were included in the present study, and they were divided into the PL group (n = 32) and PR group (n = 29). The overall response rate (ORR) (12.5%vs. 10.3%, respectively; p = 0.557) and disease control rate (DCR) (71.9%vs. 58.6%, respectively; p < 0.207) were higher in the PL group than in the PR group, but there was no statistical difference.Furthermore, median PFS and OS were not significantly different between the two groups in Kaplan-Meier survival analysis (PFS: 5.3 months vs 4.0 months, p = 0.512; OS: 14.1 months vs 13.7 months, p = 0.764 for the PL group vs PR group). The most common treatment-related adverse events (TRAEs) were hand -foot skin reaction (24/61,39.3%), hypertension (20/61,32.8%) and hypothyroidism (13/61,21.3%). The frequent TRAEs (≥Grade 3) during PD-1 inhibitors plus lenvatinib or regorafenib treatment were hand-foot skin reaction (5/29,12.4%), thrombocytopenia (2/29 6.90%) and proteinuria (n =2/32,6.25%).ConclusionsCombination of lenvatinib/regorafenib and PD-1 inhibitors is a promising therapy for HCC patients after sorafenib failure. |
| first_indexed | 2024-04-12T04:42:58Z |
| format | Article |
| id | doaj.art-f8a9d148e9e144a9973d09261ba52e40 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T04:42:58Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f8a9d148e9e144a9973d09261ba52e402022-12-22T03:47:35ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.958869958869PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenibYongkang Xu0Shumin Fu1Kai Shang2Jiayu Zeng3Ye Mao4Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, ChinaSchool of Clinical Medicine, Guizhou Medical University, Guiyang, ChinaDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaBackgroundLenvatinib, regorafenib and anti-programmed cell death protein-1 (PD-1) immunotherapy have shown promising clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure, respectively. However, the combination of the two treatments has not been reported. We compared the efficacy of PD-1 inhibitors with lenvatinib (PL) and PD-1 inhibitors plus regorafenib (PR) in patients with advanced HCC in this study.MethodsWe conducted a retrospective study of advanced HCC patients who undergone PD-1 inhibitors combined with lenvatinib or regorafenib after failure of sorafenib at Second Affiliated Hospital of Nanchang University from July 2018 and December 2020. The overall survival (OS), progression-free survival (PFS), effective rates and treatment-related adverse events (TRAEs) were investigated.ResultsIn total, 61 patients met the criteria and were included in the present study, and they were divided into the PL group (n = 32) and PR group (n = 29). The overall response rate (ORR) (12.5%vs. 10.3%, respectively; p = 0.557) and disease control rate (DCR) (71.9%vs. 58.6%, respectively; p < 0.207) were higher in the PL group than in the PR group, but there was no statistical difference.Furthermore, median PFS and OS were not significantly different between the two groups in Kaplan-Meier survival analysis (PFS: 5.3 months vs 4.0 months, p = 0.512; OS: 14.1 months vs 13.7 months, p = 0.764 for the PL group vs PR group). The most common treatment-related adverse events (TRAEs) were hand -foot skin reaction (24/61,39.3%), hypertension (20/61,32.8%) and hypothyroidism (13/61,21.3%). The frequent TRAEs (≥Grade 3) during PD-1 inhibitors plus lenvatinib or regorafenib treatment were hand-foot skin reaction (5/29,12.4%), thrombocytopenia (2/29 6.90%) and proteinuria (n =2/32,6.25%).ConclusionsCombination of lenvatinib/regorafenib and PD-1 inhibitors is a promising therapy for HCC patients after sorafenib failure.https://www.frontiersin.org/articles/10.3389/fonc.2022.958869/fullPD-1 inhibitorslenvatinibregorafenibsorafenibhepatocellular carcinoma |
| spellingShingle | Yongkang Xu Shumin Fu Kai Shang Jiayu Zeng Ye Mao PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib Frontiers in Oncology PD-1 inhibitors lenvatinib regorafenib sorafenib hepatocellular carcinoma |
| title | PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib |
| title_full | PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib |
| title_fullStr | PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib |
| title_full_unstemmed | PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib |
| title_short | PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib |
| title_sort | pd 1 inhibitors plus lenvatinib versus pd 1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib |
| topic | PD-1 inhibitors lenvatinib regorafenib sorafenib hepatocellular carcinoma |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.958869/full |
| work_keys_str_mv | AT yongkangxu pd1inhibitorspluslenvatinibversuspd1inhibitorsplusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterfailureofsorafenib AT shuminfu pd1inhibitorspluslenvatinibversuspd1inhibitorsplusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterfailureofsorafenib AT kaishang pd1inhibitorspluslenvatinibversuspd1inhibitorsplusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterfailureofsorafenib AT jiayuzeng pd1inhibitorspluslenvatinibversuspd1inhibitorsplusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterfailureofsorafenib AT yemao pd1inhibitorspluslenvatinibversuspd1inhibitorsplusregorafenibinpatientswithadvancedhepatocellularcarcinomaafterfailureofsorafenib |